Monoamine oxidases and tobacco smoking

International Journal of Neuropsychopharmacology

Volumn 4, Issue 1, 2001, Pages 33-42

  Berlin, Ivan ^a   Anthenelli, Robert M ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Monoamine oxidase A; Monoamine oxidase B; Nicotine; Psychopharmacology of smoking

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; NICOTINE;

BLOOD ANALYSIS; CEREBROSPINAL FLUID EXAMINATION; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE; TOBACCO; TOBACCO DEPENDENCE;

ANIMALS; HUMANS; MONOAMINE OXIDASE; NICOTINE; NICOTINIC AGONISTS; PLANTS, TOXIC; SMOKING; TOBACCO;

EID: 0035032372     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145701002188     Document Type: Review

References (74)

1. The biological, social and clinical bases of drug addiction: Commentary and debate
2. Platelet monoamine oxidase activity in subgroups of alcoholics and controls: Results from the Collaborative study on the Genetic of Alcoholism
3. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties
4. Human platelet monoamine oxidase changes during the menstrual cycle
5. Measurement of human cerebral monoamine oxidase type B (MAOB) activity with positron emission tomography (PET): A dose ranging study with the reversible inhibitor Ro 19-6327
6. Nicotine addiction
7. Platelet MAOB activity is inversely associated with plasma cotinine concentration
8. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers
9. Monoamine oxidase A and B activities in heavy smokers
10. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects
11. Biogenic amine adducts, monoamine oxidase inhibitors, and smoking
12. Platelet monoamine oxidase activity: Demographic characteristics contribute to enzyme activity variability
13. The biochemical high-risk paradigm: Behavioral and familial correlates of low platelet monoamine oxidase activity
14. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain
15. Attenuation of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke
16. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA
17. Tobacco control
18. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical
19. Behavioral and biochemical studies of dichlorometane fraction from the Areca catechu nut
20. Substrate- and inhibitor related characteristics of human platelet monoamine oxidase
21. Source and physiological significance of plasma 3,4-dihyrdoxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol
22. Serotonin and monoamine oxidase in mouse skin: Effects of cigarette smoke exposure
23. The effect of age on the activity and molecular properties of human brain monoamine oxidase
24. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo
25. Slow recovery of human brain MAO B after L-deprenyl (selegiline) withdrawal
26. Inhibition of monoamine oxidase B in the brains of smokers
27. Neuropharmacological actions of cigarette smoke: Brain monoamine oxidase B (MAOB) inhibition
28. Brain monoamine oxidase inhibition in cigarette smokers
29. Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers
30. Increased stress response and beta-phenylethylamine in MAOB deficient mice
31. Low CSF concentration of a dopamine metabolite in tobacco smokers
32. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking
33. Tyramine oxidase. A new enzyme system in liver
34. Nicotine and caffeine use as confounds in psychiatric studies
35. A comparison of sustained-release bupropion and placebo for smoking cessation
36. Some observations upon a new inhibitor of monoamine oxidase in brain tissue
37. A controlled trial of sustained-release bupropion, a nicotine patch, both for smoking cessation
38. Isolation and characterization of a monoamine oxidase inhibitor form tobacco leaves
39. Inhibition of monoamine oxidase A by β-carboline derivatives
40. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice
41. Some puzzling pharmacological effects of monoamine oxidase inhibitors
42. Specific deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes
43. Development of benzylamine oxidase and monoamine oxidase A and B in man
44. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca
45. Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke
46. Platelet monoamine oxidase activity and cigarette smoking
47. Platelet monoamine oxidase: Low activity in cigarette smokers
48. Low platelet monoamine oxidase activity in cigarette smokers
49. The correlation between platelet MAO activity and personality: The effect of smoking and possible mechanisms behind the correlation
50. Monoamine oxidase activity as a biological marker
51. Effect of cigarette smoke on brain monoamine oxidase activity
52. Mortality from smoking worldwide
53. Transdermal nicotine: Reduction of smoking with minimal abuse liability
54. Pharmacodynamic effects of new de-nicotinized cigarettes
55. Platelet monoamine oxidase activity and plasma 3,4-dihydroxy-phenylethylene glycol levels during the menstrual cycle
56. A randomized trial of nortritptyline for smoking cessation
57. Genome screen for platelet monoamine oxidase (MAO) activity
58. Human platelet monoamine oxidase activity in health and disease
59. Nicotine nasal spray and vapor inhaler: Abuse liability assessment
60. Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components
61. 1-tetrahydrocannabinol, inhibits human brain and liver monoamine oxidase
62. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: Partial protection against striato-nigral dopamine depletion in C57BL/6j mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment
63. Monoamine oxidase: From genes to behavior
64. Nicotine replacement therapy for smoking cessation
65. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation
66. Schizophrenia, monoamine oxidase activity, and cigarette smoking
67. Studies on the interaction between 1,2,3,4-tetrahydro-β-carboline and cigarette smoke: Potential mechanism of neuroprotection for Parkinson's disease
68. How effective is nicotine replacement therapy in helping people to stop smoking
69. Inhibition of platelet MAOB by kava pyrone-enriched extract from Piper Methysticum Foster (kava-kava)
70. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system
71. Personality traits and platelet monoamine oxidase in tobacco smokers
72. Distinct monoamine oxidase A and B populations in primate brain
73. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke